Form 4: Artivion Executive Trades Shares Under 10b5-1 Plan

Andrew M. Green, SVP at Artivion, Inc., executed a series of stock transactions on June 11, 2026, under a pre-established Rule 10b5-1 trading plan.

Summary

• Andrew M. Green, Senior Vice President of Regulatory and Quality at Artivion, Inc. (AORT), reported transactions involving common stock on June 11, 2026.
• These transactions included the exercise of stock options and the subsequent sale of shares, all conducted under a Rule 10b5-1 trading plan adopted on March 12, 2026.
• Specifically, 14,001 shares were acquired at $18.44 per share and then sold at a weighted average price of $20.707.
• Additionally, 30,000 shares were acquired at $11.03 per share and subsequently sold at a weighted average price of $20.694.
• Following these transactions, Mr. Green beneficially owns 60,259 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by an executive can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a pre-determined strategy.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading related activity.
• The sales occurred at prices higher than the exercise prices of the options, suggesting a profitable execution of the plan.
• Mr. Green continues to hold a significant number of shares (60,259) directly, indicating continued investment in the company.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market.
• The weighted average sale prices, while profitable on the exercise, represent a disposal of equity.

Risks

• The Rule 10b5-1 plan is designed to mitigate insider trading concerns, but the sale of a substantial number of shares by an executive could still be interpreted as a lack of confidence in future price appreciation by some investors.
• The weighted average sale prices for the shares were between $20.24 and $21.02, and any future price movements below these levels could be seen as a missed opportunity for the executive.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions were executed under a pre-defined plan.

Management Comments

• The option exercise and subsequent sale reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026.
• Reflects weighted average price. Range of prices were between $20.25 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• Reflects weighted average price. Range of prices were between $20.24 to $21.02. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
• Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023.
• Stock options vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions are common in the biotechnology and medical device sectors, where stock-based compensation is prevalent. The use of Rule 10b5-1 plans is a standard practice for executives to manage their stock holdings while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a senior executive as a potential negative signal, although the Rule 10b5-1 plan provides a mitigating context.
• Employees: May view the executive's stock sales in conjunction with their own stock options or grants, potentially influencing their perception of the company's stock performance.
• Management: The transactions are part of a planned strategy by Mr. Green to manage his personal finances and comply with regulations.

Next Steps

• The reporting person may be required to provide further details on the specific prices of shares sold upon request from regulatory bodies, the issuer, or security holders.
• Future transactions by Mr. Green would be reported on subsequent Form 4 filings.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Options, Stock Sale, Artivion, AORT, Andrew M. Green, Beneficial Ownership, Executive Compensation